doi: 10.1161/01.RES.0000231259.29646.74
© 2006 American Heart Association, Inc.
Editorials |
When Hearts Fail So Does Skeletal Muscle
Breaking a Vicious Cycle
From the Center for Cardiovascular Research, University of Illinois at Chicago Department of Physiology & Biophysics.
Correspondence to R. John Solaro, PhD, Department of Physiology & Biophysics (M/C 901), University of Illinois at Chicago, College of Medicine, 835 S Wolcott Ave, Chicago, IL 60612. E-mail solarorj{at}uic.edu
See related article, pages 1514–1519
Key Words: hypertrophy • congestive heart failure • animal models of human disease • heart failure
 |
Introduction |
|---|
 Top Introduction ROS-Induced Alterations in...Abnormal Skeletal Muscle...PerspectivesReferences |
|---|
In heart failure, keeping up with the oxygen demands of working skeletal muscles becomes compromised during exercise. As if this situation is not bad enough, as with many aspects of the heart failure syndrome, there are more vicious mechanisms at work. It has been known for some time that skeletal muscle function is also depressed in patients and animals in heart failure. The depression has been attributed to disuse atrophy, changes in fiber types, and abnormal metabolism.1,2 Thus the impaired cardiac function in patients not only limits exercise, but depressed skeletal muscle function itself inhibits the ability to exercise causing further depression of cardiac function.
In the current issue of Circulation Research, Lunde et al3 report evidence which supports the concept that heart failure leads to a primary depression in the force generating capacity of skeletal muscle, and which provides new insights into the mechanism. Their approach involved investigation of single living fibers isolated from the soleus muscle of rats whose hearts had been stressed by ligation of the coronary arteries (MI mice) 6 weeks before the experiments. In technically demanding experiments, Lunde et al3 simultaneously determined the force and intracellular Ca2+ ([Ca2+]i) in single soleus cells under nonfatiguing and fatiguing conditions. Under nonfatiguing conditions contraction and Ca2+- transients of sham and MI-fibers were not significantly different, but there was a depression in the levels of [Ca2+]i during the tetani. Compared with controls, MI-fibers had no major changes in expression of membrane proteins involved in Ca2+ regulation. After fatigue, the tetanic force developed in MI-fibers was significantly decreased in the absence of a further change in the level of tetanic [Ca2+]i. In fibers from shams the tetanic force was less affected and associated with a decrease in tetanic [Ca2+]i. These data provide the first evidence that, when bathed in identical solutions, intact single slow skeletal fibers from MI-stressed animals fatigue more severely than controls in the absence of major [Ca2+]i alterations. Earlier determinations of force and intracellular Ca2+, as measured using the aequorin technique, indicated a defect in excitation contraction coupling.4 What’s new in the work reported by Lunde et al3 is the explicit identification of a mechanism at the level of the single cell involving a defect in skeletal muscle function during fatigue related to an alteration in the response of the sarcomeres to Ca2+ rather than a depression of Ca2+ delivery to the sarcomeres.
A depression in sarcomeric response to Ca2+ also appears to be an important mechanism in failure of the heart. Evidence supporting this hypothesis has been reviewed elsewhere5,6 and indicates that the mechanisms involve posttranslational modifications involving phosphorylation,7 proteolysis,8 and generation of reactive oxygen species (ROS).7 Familial cardiomyopathies genetically linked to mutations in sarcomeric proteins also involve altered sarcomeric response to Ca2+.8 In this case there is no dispute that the primary defect resides in the sarcomeric proteins.
|
ROS-Induced Alterations in Sarcomere Response of Skeletal Muscle to Ca2+ in Heart Failure |
|---|
|
TopIntroductionROS-Induced Alterations in...Abnormal Skeletal Muscle...PerspectivesReferences |
|---|
An altered contraction of skeletal muscle that occurs without a change in [Ca2+]i implies a cardiac dysfunction–induced modification of the skeletal sarcomeric proteins. The mechanism may involve an increase in skeletal muscle ROS resulting from mitochondrial dysfunction. Hearts of MI rats exhibit increased mitochondrial ROS production, increased protein oxidation, and a decrease in the force–frequency relationship, which can be reversed by treatment with a ROS scavenger.9 This heart failure induced increase in ROS may be central to the development of skeletal muscle dysfunction at the sarcomeric level.
Increased generation of ROS in muscle has been implicated in protein modification, increased fibrosis, and an increase in the rate of extracellular matrix turnover, and may cause the modification or degradation of sarcomeric proteins.10 The degradation of both troponin I and troponin T have been demonstrated to occur in cardiac muscle resulting from ischemia-reperfusion11–13 and in skeletal muscle resulting from hypoxia/fatigue.14,15 The degradation products of troponin I and troponin T directly affect muscle contraction to alter maximal force production and Ca2+ sensitivity.13,14 Furthermore, fatiguing stimulation is presumably exacerbated in skeletal fibers of heart failure patients leading to increased hypoxia. Yet in the report by Lind et al3 there was a full restoration of maximal tetanic force with application of caffeine after 30 minutes of recovery from fatigue. This observation suggests, but does not rule out, the initial increase in Ca2+ sensitivity and the decrease in developed force after fatigue of MI skeletal muscles was the result of a readily reversible sarcomeric protein modification and not a degradation event.
As pointed out by Lunde et al,3 it is likely that their findings are related to ROS generation. Among the sarcomeric proteins that may be altered by ROS, we think that actin and tropomyosin may be particularly important. Direct evidence linking the ROS modification of tropomyosin and actin to the alteration of skeletal muscle function is lacking, however the central role of these proteins in the Ca2+ regulation of muscle activation strongly suggests their modification could affect muscle function. ROS-induced modification of cardiac tropomyosin in heart failure,16 as well as in skeletal muscles after recovery from MI,17 has been reported. Although the functional significance of the ROS-induced tropomyosin modifications has not been directly investigated, the significant effects of point mutations8 and phosphorylation18 of Tm indicate that oxidative modification of tropomyosin could alter muscle contraction. Muscle actin is also modified in both cardiac and skeletal muscles by oxidative stress. After ischemia–reperfusion both cardiac and skeletal muscle actin exhibit ROS modification.16,17,19 In a rat model of MI, Chen and Ogut19 demonstrated a reduction in maximally developed force of skinned cardiac trabeculae containing the ROS modified actin, as well as a depressed in vitro polymerization and cooperativity of binding to tropomyosin compared with unmodified actin.
|
Abnormal Skeletal Muscle Function in Heart Failure Most Likely Represents the Integrated Effects of Multiple Factors |
|---|
|
TopIntroductionROS-Induced Alterations in...Abnormal Skeletal Muscle...PerspectivesReferences |
|---|
Factors in addition to ROS-induced modifications are likely to be important in the altered response of skeletal muscle to intracellular Ca2+ in heart failure. There is substantial evidence that alterations in intracellular milieu associated with fatigue depress force through direct effects on the myofilaments. The alterations most prominent in this effect are acidosis and an increase in inorganic phosphate (Pi) arising from the breakdown of creatine phosphate.20 An important and yet poorly understood question is whether skeletal sarcomeric proteins modified by ROS or proteolysis respond differently than controls to a rise in Pi and H+ in the intracellular milieu. There is evidence that this might occur from studies of skinned fiber preparations containing troponin T with a point mutation linked to familial hypertrophic cardiomyopathy.21 Whether ROS-induced modification or proteolysis of skeletal sarcomeric proteins in heart failure exacerbates or ameliorates the effects of acidosis or increased Pi on the force-Ca2+ relation has not yet been investigated to our knowledge.
|
Perspectives |
|---|
|
TopIntroductionROS-Induced Alterations in...Abnormal Skeletal Muscle...PerspectivesReferences |
|---|
The findings of Lunde et al3 and others beg the question as to whether there is anything that can be done to help break the viscous cycle of altered function in both heart and skeletal muscle. Several studies indicate that there is hope. One of these studies reports that carvedilol, a beta-1 and beta-2 adrenergic receptor blocker commonly used to treat heart failure, also has a remarkable ability to block production of ROS.22 Treatment of rats in heart failure with carvedilol prevented the ROS modification of skeletal sarcomeric proteins and restored the depressed force generation that occurred in untreated rats.17 Bisoprolol, a selective beta-1 blocker, could only weakly prevent ROS modification and had no effect on function. Reversal of oxidative damage to sarcomeric proteins can also occur with exercise. Thus restoration of exercise capacity in heart failure by carvedilol has an added advantage. Whatever the case, the results reported by Lunde et al3 emphasize the importance of developing and evaluating therapies with consideration of effects on striated muscle fibers in both cardiac and skeletal muscles.
|
Acknowledgments |
|---|
Sources of Funding
This work was supported by NIH Grants R37 HL 22231-28, RO1 HL 64035-06, and PO1 HL 62426-06.
Disclosures
Brandon J. Biesiadecki is a collaborator on HL 22231. R. John Solaro is the PI of grant ROI HL 22231, ROI HL 64035, and ROI HL 62426.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
|
TopIntroductionROS-Induced Alterations in...Abnormal Skeletal Muscle...PerspectivesReferences |
|---|
1. Drexler H, Coats AJ. Explaining fatigue in congestive heart failure. Ann Rev Med. 1996; 47: 241–246.[CrossRef][Medline] [Order article via Infotrieve]
2. Dalla Libera L, Vescovo G. Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimeric view of inflammation? Curr Opin Clin Nutr Metab Care. 2004; 7: 435–441.[CrossRef][Medline] [Order article via Infotrieve]
3. Lunde PK, Sejersted OM, Thorud H-M S, Tonnessen T, Henriksen UL, Christensen G, Westerblad H, Bruton J. Effects of congestive heart failure on Ca2+ handling in skeletal muscle during fatigue. Circ Res. 2006; 98: 1514–1519.
4. Perreault CL, Gonzalez-Serratos H, Litwin SE, Sun X, Franzini-Armstrong C, Morgan JP. Alterations in contractility and intracellular Ca2+-transients in isolated bundles of skeletal muscle fibers from rats with chronic heart failure. Circ Res. 1993; 73: 405–412.
5. de Tombe PP, Solaro RJ. Integration of cardiac myofilament activity and regulation with pathways signaling hypertrophy and failure. Ann Biomed Eng. 2000; 28: 991–1001.[CrossRef][Medline] [Order article via Infotrieve]
6. Marston SB, Redwood CS. Modulation of thin filament activation by breakdown or isoform switching of thin filament proteins: physiological and pathological implications. Circ Res. 2003; 93: 1170–1178.
7. Minhas KM, Saraiva RM, Schuleri KH, Lehrke S, Zheng M, Saliaris AP, Berry CE, Vandegaer KM, Li D, Hare JM. Xanthine oxido-reductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 2006; 98: 271–279.
8. Tardiff JC. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev. 2005; 10: 237–248.[CrossRef][Medline] [Order article via Infotrieve]
9. Supinski GS, Calahan LA. Diaphragmatic free radical generation increases in an animal model of heart failure. J Appl Physiol. 2005; 99: 1078–1084.
10. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res. In press.
11. Yu Z-B, Xhang L-F, Jin J-P. A proteolytic NH2-terminal truncation of cardiac troponin I that is up-regulated in simulated microgravity. J Biol Chem. 2001; 276: 15753–15760.
12. Communal C, Sumandea M, deTombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci. 2002; 99: 6252–6256.
13. McDonough JL, Arrell DK, VanEyk JE. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res. 1999; 84: 9–20.
14. Brotto MP, VanLeyen SA, Brotto LS, Jin J-P, Nosek CM, Nosek TM. Hypoxia/fatigue-induced degradation of troponin I and troponin C: new insights into physiologic muscle fatigue. Eur J Physiol. 2001; 442: 738–744.[CrossRef][Medline] [Order article via Infotrieve]
15. Simpson JA, VanEyk JE, Iscoe S. Hypoxemia-induced modification of troponin I and T in canine diaphragm. J Appl Physiol. 2000; 88: 753–760.
16. Canton M, Skyschally A, Menabo R, Boengler K, Gres P, Schulz R, Haude M, Erbel R, Di Lisa F, Heusch G. Oxidative modification of tropomyosin and myocardial dysfunction following coronary micro-embolization. Eur Heart J. 2006;2006; 27: 875–881.
17. Dalla Libera L, Ravara B, Gobbo V, Danieli Betto D, Germinario E, Angelini A, Vescovo G. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol. 2005; 38: 803–807.[CrossRef][Medline] [Order article via Infotrieve]
18. Heeley DH. Investigation of the effects of phosphorylation of rabbit striated muscle 
-tropomyosin and rabbit skeletal muscle troponin T. Eur J Biochem. 1994; 221: 129–137.[Medline]
[Order article via Infotrieve]
19. Chen F, Ogut O. Decline of contractility during ischemia-reperfusion injury: actin glutathionylation and its effect on allosteric interaction with tropomyosin. Am J Physiol Cell Physiol. 2006; 290: C719–C727.
20. Godt RE, Nosek TM. Changes of intracellular milieu with fatigue or hypoxia depress contraction of skinned rabbit skeletal and cardiac muscle. J Physiol. 1989; 412: 155–180.
21. Solaro RJ, Varghese J, Marian AJ, Chandra M. Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q. Basic Res Cardiol. 2002; 97: I102–I110.[Medline] [Order article via Infotrieve]
22. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magrino C. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation. 2000; 101: 122–124.
Related Article:
Circ. Res. 2006 98: 1514-1519.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||